Skip to main content
Erschienen in: Strahlentherapie und Onkologie 11/2014

01.10.2014 | Original article

Mesenchymal stem cells are sensitive to treatment with kinase inhibitors and ionizing radiation

verfasst von: Nils H. Nicolay, M.D., Ph.D., Eva Sommer, D.V.M., Ramon Lopez Perez, M.Sc., Ute Wirkner, Ph.D., Tilman Bostel, M.D., Anthony D. Ho, M.D., Michael Lahn, Ph.D., Jürgen Debus, M.D., Ph.D., Rainer Saffrich, Ph.D, Peter E. Huber, M.D., Ph.D

Erschienen in: Strahlentherapie und Onkologie | Ausgabe 11/2014

Einloggen, um Zugang zu erhalten

Abstract

Introduction

Mesenchymal stem cells (MSCs) can regenerate damaged tissues and may therefore be of importance for normal tissue repair after cancer treatment. Small molecule receptor kinase inhibitors (RKIs) have recently been introduced into cancer treatment. However, the influence of these drugs—particularly in combination with radiotherapy—on the survival of MSCs is largely unknown.

Methods

The sensitivity of human primary MSCs from healthy volunteers and primary human fibroblast cells to small molecule kinase inhibitors of the vascular endothelial growth factor (VEGF), platelet-derived growth factor (PDGF) and transforming growth factor β (TGFβ) receptors, as well to inhibitors of c-Kit, was examined in combination with ionizing radiation (IR); cell survival and proliferation were assessed. Expression patterns of different kinase receptors and ligands were investigated using gene arrays.

Results

MSCs were highly sensitive to the tyrosine kinase inhibitors SU14816 (imatinib) and SU11657 (sunitinib), but showed only moderate sensitivity to the selective TGFβ receptor 1 inhibitor LY2109761. Primary adult human fibroblasts were comparably resistant to all three inhibitors. The addition of IR had an additive or supra-additive effect in the MSCs, but this was not the case for differentiated fibroblasts. Proliferation was markedly reduced in MSCs following kinase inhibition, both with and without IR. Gene expression analysis revealed high levels of the PDGF α and β receptors, and lower levels of the TGFβ receptor 2 and Abl kinase. IR did not alter the expression of kinase receptors or their respective ligands in either MSCs or adult fibroblasts.

Conclusion

These data show that MSCs are highly sensitive to RKIs and combination treatments incorporating IR. Expression analyses suggest that high levels of PDGF receptors may contribute to this effect.
Literatur
1.
Zurück zum Zitat Kalinina NI, Sysoeva VY, Rubina KA, Parfenova YV, Tkachuk VA (2011) Mesenchymal stem cells in tissue growth and repair. Acta Naturae 3:30–37PubMedCentralPubMed Kalinina NI, Sysoeva VY, Rubina KA, Parfenova YV, Tkachuk VA (2011) Mesenchymal stem cells in tissue growth and repair. Acta Naturae 3:30–37PubMedCentralPubMed
2.
Zurück zum Zitat Hong HS, Kim YH, Son Y (2012) Perspectives on mesenchymal stem cells: tissue repair, immune modulation, and tumor homing. Arch Pharm Res 35:201–211PubMedCrossRef Hong HS, Kim YH, Son Y (2012) Perspectives on mesenchymal stem cells: tissue repair, immune modulation, and tumor homing. Arch Pharm Res 35:201–211PubMedCrossRef
3.
Zurück zum Zitat Hayes M, Curley G, Ansari B, Laffey JG (2012) Clinical review: Stem cell therapies for acute lung injury/acute respiratory distress syndrome—hope or hype? Crit Care 16:205PubMedCentralPubMedCrossRef Hayes M, Curley G, Ansari B, Laffey JG (2012) Clinical review: Stem cell therapies for acute lung injury/acute respiratory distress syndrome—hope or hype? Crit Care 16:205PubMedCentralPubMedCrossRef
4.
Zurück zum Zitat Qi Y, Feng G, Yan W (2012) Mesenchymal stem cell-based treatment for cartilage defects in osteoarthritis. Mol Biol Rep 39:5683–5689PubMedCrossRef Qi Y, Feng G, Yan W (2012) Mesenchymal stem cell-based treatment for cartilage defects in osteoarthritis. Mol Biol Rep 39:5683–5689PubMedCrossRef
5.
Zurück zum Zitat Williams AR, Hare JM (2011) Mesenchymal stem cells: biology, pathophysiology, translational findings, and therapeutic implications for cardiac disease. Circ Res 109:923–940PubMedCentralPubMedCrossRef Williams AR, Hare JM (2011) Mesenchymal stem cells: biology, pathophysiology, translational findings, and therapeutic implications for cardiac disease. Circ Res 109:923–940PubMedCentralPubMedCrossRef
6.
Zurück zum Zitat Schmidt M, Haagen J, Noack R, Siegemund A, Gabriel P, Dörr W (2014) Effects of bone marrow or mesenchymal stem cell transplantation on oral mucositis (mouse) induced by fractionated irradiation. Strahlenther Onkol 190:399–404PubMedCrossRef Schmidt M, Haagen J, Noack R, Siegemund A, Gabriel P, Dörr W (2014) Effects of bone marrow or mesenchymal stem cell transplantation on oral mucositis (mouse) induced by fractionated irradiation. Strahlenther Onkol 190:399–404PubMedCrossRef
7.
Zurück zum Zitat Dörr W, Herrmann T, Baumann M (2014) Application of organ tolerance dose-constraints in clinical studies in radiation oncology. Strahlenther Onkol 190:399–404 Dörr W, Herrmann T, Baumann M (2014) Application of organ tolerance dose-constraints in clinical studies in radiation oncology. Strahlenther Onkol 190:399–404
8.
Zurück zum Zitat Goetze K, Meyer SS, Yaromina A, Zips D, Baumann M, Mueller-Klieser W (2013) Glycolysis-related gene induction and ATP reduction during fractionated irradiation. Markers for radiation responsiveness of human tumor xenografts. Strahlenther Onkol 189:782–788PubMedCrossRef Goetze K, Meyer SS, Yaromina A, Zips D, Baumann M, Mueller-Klieser W (2013) Glycolysis-related gene induction and ATP reduction during fractionated irradiation. Markers for radiation responsiveness of human tumor xenografts. Strahlenther Onkol 189:782–788PubMedCrossRef
10.
Zurück zum Zitat Milas L, Raju U, Liao Z, Ajani J (2005) Targeting molecular determinants of tumor chemo-radioresistance. Semin Oncol 32:78–81CrossRef Milas L, Raju U, Liao Z, Ajani J (2005) Targeting molecular determinants of tumor chemo-radioresistance. Semin Oncol 32:78–81CrossRef
11.
Zurück zum Zitat Strasser H, Grabenbauer GG, Sprung CN, Sauer R, Distel LV (2007) DNA double-strand break induction and repair in irradiated lymphoblastoid, fibroblast cell lines and white blood cells from ATM, NBS and radiosensitive patients. Strahlenther Onkol 183:447–453PubMedCrossRef Strasser H, Grabenbauer GG, Sprung CN, Sauer R, Distel LV (2007) DNA double-strand break induction and repair in irradiated lymphoblastoid, fibroblast cell lines and white blood cells from ATM, NBS and radiosensitive patients. Strahlenther Onkol 183:447–453PubMedCrossRef
12.
Zurück zum Zitat Herskind C, Bamberg M, Rodemann HP (1998) The role of cytokines in the development of normal-tissue reactions after radiotherapy. Strahlenther Onkol 174:12–15PubMed Herskind C, Bamberg M, Rodemann HP (1998) The role of cytokines in the development of normal-tissue reactions after radiotherapy. Strahlenther Onkol 174:12–15PubMed
13.
Zurück zum Zitat Bonner JA, Harari PM, Giralt J, Cohen RB, Jones CU, Sur RK, Raben D, Baselga J, Spencer SA, Zhu J et al (2010) Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol 11:21–28PubMedCrossRef Bonner JA, Harari PM, Giralt J, Cohen RB, Jones CU, Sur RK, Raben D, Baselga J, Spencer SA, Zhu J et al (2010) Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol 11:21–28PubMedCrossRef
14.
Zurück zum Zitat Hoff PM, Hochhaus A, Pestalozzi BC, Tebbutt NC, Li J, Kim TW, Koynov KD, Kurteva G, Pinter T, Cheng Y et al (2012) Cediranib plus FOLFOX/CAPOX versus placebo plus FOLFOX/CAPOX in patients with previously untreated metastatic colorectal cancer: a randomized, double-blind, phase III study (HORIZON II). J Clin Oncol 30:3596–3603PubMedCrossRef Hoff PM, Hochhaus A, Pestalozzi BC, Tebbutt NC, Li J, Kim TW, Koynov KD, Kurteva G, Pinter T, Cheng Y et al (2012) Cediranib plus FOLFOX/CAPOX versus placebo plus FOLFOX/CAPOX in patients with previously untreated metastatic colorectal cancer: a randomized, double-blind, phase III study (HORIZON II). J Clin Oncol 30:3596–3603PubMedCrossRef
15.
Zurück zum Zitat Huber PE, Bischof M, Jenne J, Heiland S, Peschke P, Saffrich R, Grone HJ, Debus J, Lipson KE, Abdollahi A (2005) Trimodal cancer treatment: beneficial effects of combined antiangiogenesis, radiation, and chemotherapy. Cancer Res 65:3643–3655PubMedCrossRef Huber PE, Bischof M, Jenne J, Heiland S, Peschke P, Saffrich R, Grone HJ, Debus J, Lipson KE, Abdollahi A (2005) Trimodal cancer treatment: beneficial effects of combined antiangiogenesis, radiation, and chemotherapy. Cancer Res 65:3643–3655PubMedCrossRef
16.
Zurück zum Zitat Timke C, Zieher H, Roth A, Hauser K, Lipson KE, Weber KJ, Debus J, Abdollahi A, Huber PE (2008) Combination of vascular endothelial growth factor receptor/platelet-derived growth factor receptor inhibition markedly improves radiation tumor therapy. Clin Cancer Res 14:2210–2219PubMedCrossRef Timke C, Zieher H, Roth A, Hauser K, Lipson KE, Weber KJ, Debus J, Abdollahi A, Huber PE (2008) Combination of vascular endothelial growth factor receptor/platelet-derived growth factor receptor inhibition markedly improves radiation tumor therapy. Clin Cancer Res 14:2210–2219PubMedCrossRef
17.
Zurück zum Zitat Zhang M, Kleber S, Rohrich M, Timke C, Han N, Tuettenberg J, Martin-Villalba A, Debus J, Peschke P, Wirkner U et al (2011) Blockade of TGF-beta signaling by the TGFbetaR-I kinase inhibitor LY2109761 enhances radiation response and prolongs survival in glioblastoma. Cancer Res 71:7155–7167PubMedCrossRef Zhang M, Kleber S, Rohrich M, Timke C, Han N, Tuettenberg J, Martin-Villalba A, Debus J, Peschke P, Wirkner U et al (2011) Blockade of TGF-beta signaling by the TGFbetaR-I kinase inhibitor LY2109761 enhances radiation response and prolongs survival in glioblastoma. Cancer Res 71:7155–7167PubMedCrossRef
18.
Zurück zum Zitat Flechsig P, Dadrich M, Bickelhaupt S, Jenne J, Hauser K, Timke C, Peschke P, Hahn EW, Grone HJ, Yingling J et al (2012) LY2109761 attenuates radiation-induced pulmonary murine fibrosis via reversal of TGF-beta and BMP-associated proinflammatory and proangiogenic signals. Clin Cancer Res 18:3616–3627PubMedCrossRef Flechsig P, Dadrich M, Bickelhaupt S, Jenne J, Hauser K, Timke C, Peschke P, Hahn EW, Grone HJ, Yingling J et al (2012) LY2109761 attenuates radiation-induced pulmonary murine fibrosis via reversal of TGF-beta and BMP-associated proinflammatory and proangiogenic signals. Clin Cancer Res 18:3616–3627PubMedCrossRef
19.
Zurück zum Zitat Richeldi L, Costabel U, Selman M, Kim DS, Hansell DM, Nicholson AG, Brown KK, Flaherty KR, Noble PW, Raghu G et al (2011) Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis. N Engl J Med 365:1079–1087PubMedCrossRef Richeldi L, Costabel U, Selman M, Kim DS, Hansell DM, Nicholson AG, Brown KK, Flaherty KR, Noble PW, Raghu G et al (2011) Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis. N Engl J Med 365:1079–1087PubMedCrossRef
20.
Zurück zum Zitat Abdollahi A, Li M, Ping G, Plathow C, Domhan S, Kiessling F, Lee LB, McMahon G, Grone HJ, Lipson KE et al (2005) Inhibition of platelet-derived growth factor signaling attenuates pulmonary fibrosis. J Exp Med 201:925–935PubMedCentralPubMedCrossRef Abdollahi A, Li M, Ping G, Plathow C, Domhan S, Kiessling F, Lee LB, McMahon G, Grone HJ, Lipson KE et al (2005) Inhibition of platelet-derived growth factor signaling attenuates pulmonary fibrosis. J Exp Med 201:925–935PubMedCentralPubMedCrossRef
22.
Zurück zum Zitat Wagner W, Wein F, Seckinger A, Frankhauser M, Wirkner U, Krause U, Blake J, Schwager C, Eckstein V, Ansorge W et al (2005) Comparative characteristics of mesenchymal stem cells from human bone marrow, adipose tissue, and umbilical cord blood. Exp Hematol 33:1402–1416PubMedCrossRef Wagner W, Wein F, Seckinger A, Frankhauser M, Wirkner U, Krause U, Blake J, Schwager C, Eckstein V, Ansorge W et al (2005) Comparative characteristics of mesenchymal stem cells from human bone marrow, adipose tissue, and umbilical cord blood. Exp Hematol 33:1402–1416PubMedCrossRef
23.
Zurück zum Zitat Nicolay NH, Sommer E, Lopez R, Wirkner U, Trinh T, Sisombath S, Debus J, Ho AD, Saffrich R, Huber PE (2013) Mesenchymal stem cells retain their defining stem cell characteristics after exposure to ionizing radiation. Int J Radiat Oncol Biol Phys 87:1171–1178PubMedCrossRef Nicolay NH, Sommer E, Lopez R, Wirkner U, Trinh T, Sisombath S, Debus J, Ho AD, Saffrich R, Huber PE (2013) Mesenchymal stem cells retain their defining stem cell characteristics after exposure to ionizing radiation. Int J Radiat Oncol Biol Phys 87:1171–1178PubMedCrossRef
24.
Zurück zum Zitat Franken NA, Rodermond HM, Stap J, Haveman J, van Bree C (2006) Clonogenic assay of cells in vitro. Nat Protoc 1:2315–2319PubMedCrossRef Franken NA, Rodermond HM, Stap J, Haveman J, van Bree C (2006) Clonogenic assay of cells in vitro. Nat Protoc 1:2315–2319PubMedCrossRef
25.
Zurück zum Zitat Melisi D, Ishiyama S, Sclabas GM, Fleming JB, Xia Q, Tortora G, Abbruzzese JL, Chiao PJ (2008) LY2109761, a novel transforming growth factor beta receptor type I and type II dual inhibitor, as a therapeutic approach to suppressing pancreatic cancer metastasis. Mol Cancer Ther 7:829–840PubMedCentralPubMedCrossRef Melisi D, Ishiyama S, Sclabas GM, Fleming JB, Xia Q, Tortora G, Abbruzzese JL, Chiao PJ (2008) LY2109761, a novel transforming growth factor beta receptor type I and type II dual inhibitor, as a therapeutic approach to suppressing pancreatic cancer metastasis. Mol Cancer Ther 7:829–840PubMedCentralPubMedCrossRef
26.
Zurück zum Zitat Fransvea E, Angelotti U, Antonaci S, Giannelli G (2008) Blocking transforming growth factor-beta up-regulates E-cadherin and reduces migration and invasion of hepatocellular carcinoma cells. Hepatology 47:1557–1566PubMedCrossRef Fransvea E, Angelotti U, Antonaci S, Giannelli G (2008) Blocking transforming growth factor-beta up-regulates E-cadherin and reduces migration and invasion of hepatocellular carcinoma cells. Hepatology 47:1557–1566PubMedCrossRef
27.
Zurück zum Zitat Buchdunger E, O’Reilly T, Wood J (2002) Pharmacology of imatinib (STI571). Eur J Cancer 38:528–536.CrossRef Buchdunger E, O’Reilly T, Wood J (2002) Pharmacology of imatinib (STI571). Eur J Cancer 38:528–536.CrossRef
28.
Zurück zum Zitat Backman U, Christofferson R (2005) The selective class III/V receptor tyrosine kinase inhibitor SU11657 inhibits tumor growth and angiogenesis in experimental neuroblastomas grown in mice. Pediatr Res 57:690–695PubMedCrossRef Backman U, Christofferson R (2005) The selective class III/V receptor tyrosine kinase inhibitor SU11657 inhibits tumor growth and angiogenesis in experimental neuroblastomas grown in mice. Pediatr Res 57:690–695PubMedCrossRef
29.
Zurück zum Zitat Kantarjian H, Sawyers C, Hochhaus A, Guilhot F, Schiffer C, Gambacorti-Passerini C, Niederwieser D, Resta D, Capdeville R, Zoellner U et al (2002) Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med 346:645–652PubMedCrossRef Kantarjian H, Sawyers C, Hochhaus A, Guilhot F, Schiffer C, Gambacorti-Passerini C, Niederwieser D, Resta D, Capdeville R, Zoellner U et al (2002) Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med 346:645–652PubMedCrossRef
30.
Zurück zum Zitat Cain JA, Grisolano JL, Laird AD, Tomasson MH (2004) Complete remission of TEL-PDGFRB-induced myeloproliferative disease in mice by receptor tyrosine kinase inhibitor SU11657. Blood 104:561–564PubMedCrossRef Cain JA, Grisolano JL, Laird AD, Tomasson MH (2004) Complete remission of TEL-PDGFRB-induced myeloproliferative disease in mice by receptor tyrosine kinase inhibitor SU11657. Blood 104:561–564PubMedCrossRef
31.
Zurück zum Zitat Bouquet F, Pal A, Pilones KA, Demaria S, Hann B, Akhurst RJ, Babb JS, Lonning SM, DeWyngaert JK, Formenti SC et al (2011) TGFbeta1 inhibition increases the radiosensitivity of breast cancer cells in vitro and promotes tumor control by radiation in vivo. Clin Cancer Res 17:6754–6765PubMedCentralPubMedCrossRef Bouquet F, Pal A, Pilones KA, Demaria S, Hann B, Akhurst RJ, Babb JS, Lonning SM, DeWyngaert JK, Formenti SC et al (2011) TGFbeta1 inhibition increases the radiosensitivity of breast cancer cells in vitro and promotes tumor control by radiation in vivo. Clin Cancer Res 17:6754–6765PubMedCentralPubMedCrossRef
32.
Zurück zum Zitat Borriello A, Caldarelli I, Basile MA, Bencivenga D, Tramontano A, Perrotta S, Della Ragione F, Oliva A (2011) The tyrosine kinase inhibitor dasatinib induces a marked adipogenic differentiation of human multipotent mesenchymal stromal cells. PloS one 6:e28555PubMedCentralPubMedCrossRef Borriello A, Caldarelli I, Basile MA, Bencivenga D, Tramontano A, Perrotta S, Della Ragione F, Oliva A (2011) The tyrosine kinase inhibitor dasatinib induces a marked adipogenic differentiation of human multipotent mesenchymal stromal cells. PloS one 6:e28555PubMedCentralPubMedCrossRef
33.
Zurück zum Zitat Jonsson S, Hjorth-Hansen H, Olsson B, Wadenvik H, Sundan A, Standal T (2012) Imatinib inhibits proliferation of human mesenchymal stem cells and promotes early but not late osteoblast differentiation in vitro. J Bone Miner Metab 30:119–123PubMedCrossRef Jonsson S, Hjorth-Hansen H, Olsson B, Wadenvik H, Sundan A, Standal T (2012) Imatinib inhibits proliferation of human mesenchymal stem cells and promotes early but not late osteoblast differentiation in vitro. J Bone Miner Metab 30:119–123PubMedCrossRef
34.
Zurück zum Zitat Plattner R, Koleske AJ, Kazlauskas A, Pendergast AM (2004) Bidirectional signaling links the Abelson kinases to the platelet-derived growth factor receptor. Mol Cell Biol 24:2573–2583PubMedCentralPubMedCrossRef Plattner R, Koleske AJ, Kazlauskas A, Pendergast AM (2004) Bidirectional signaling links the Abelson kinases to the platelet-derived growth factor receptor. Mol Cell Biol 24:2573–2583PubMedCentralPubMedCrossRef
35.
Zurück zum Zitat Ball SG, Shuttleworth CA, Kielty CM (2007) Platelet-derived growth factor receptor-alpha is a key determinant of smooth muscle alpha-actin filaments in bone marrow-derived mesenchymal stem cells. Int J Biochem Cell Biol 39:379–391PubMedCrossRef Ball SG, Shuttleworth CA, Kielty CM (2007) Platelet-derived growth factor receptor-alpha is a key determinant of smooth muscle alpha-actin filaments in bone marrow-derived mesenchymal stem cells. Int J Biochem Cell Biol 39:379–391PubMedCrossRef
36.
Zurück zum Zitat Ng F, Boucher S, Koh S, Sastry KS, Chase L, Lakshmipathy U, Choong C, Yang Z, Vemuri MC, Rao MS et al (2008) PDGF, TGF-beta, and FGF signaling is important for differentiation and growth of mesenchymal stem cells (MSCs): transcriptional profiling can identify markers and signaling pathways important in differentiation of MSCs into adipogenic, chondrogenic, and osteogenic lineages. Blood 112:295–307PubMedCrossRef Ng F, Boucher S, Koh S, Sastry KS, Chase L, Lakshmipathy U, Choong C, Yang Z, Vemuri MC, Rao MS et al (2008) PDGF, TGF-beta, and FGF signaling is important for differentiation and growth of mesenchymal stem cells (MSCs): transcriptional profiling can identify markers and signaling pathways important in differentiation of MSCs into adipogenic, chondrogenic, and osteogenic lineages. Blood 112:295–307PubMedCrossRef
37.
Zurück zum Zitat Sweeny L, Zimmermann TM, Liu Z, Rosenthal EL (2012) Evaluation of tyrosine receptor kinases in the interactions of head and neck squamous cell carcinoma cells and fibroblasts. Oral Oncol 48:1242–1249PubMedCentralPubMedCrossRef Sweeny L, Zimmermann TM, Liu Z, Rosenthal EL (2012) Evaluation of tyrosine receptor kinases in the interactions of head and neck squamous cell carcinoma cells and fibroblasts. Oral Oncol 48:1242–1249PubMedCentralPubMedCrossRef
38.
Zurück zum Zitat Donovan J, Shiwen X, Norman J, Abraham D (2013) Platelet-derived growth factor alpha and beta receptors have overlapping functional activities towards fibroblasts. Fibrogenesis Tissue Repair 6:10PubMedCentralPubMedCrossRef Donovan J, Shiwen X, Norman J, Abraham D (2013) Platelet-derived growth factor alpha and beta receptors have overlapping functional activities towards fibroblasts. Fibrogenesis Tissue Repair 6:10PubMedCentralPubMedCrossRef
39.
Zurück zum Zitat Holdhoff M, Kreuzer KA, Appelt C, Scholz R, Na IK, Hildebrandt B, Riess H, Jordan A, Schmidt CA, Van Etten RA et al (2005) Imatinib mesylate radiosensitizes human glioblastoma cells through inhibition of platelet-derived growth factor receptor. Blood Cells Mol Dis 34:181–185PubMedCrossRef Holdhoff M, Kreuzer KA, Appelt C, Scholz R, Na IK, Hildebrandt B, Riess H, Jordan A, Schmidt CA, Van Etten RA et al (2005) Imatinib mesylate radiosensitizes human glioblastoma cells through inhibition of platelet-derived growth factor receptor. Blood Cells Mol Dis 34:181–185PubMedCrossRef
40.
Zurück zum Zitat Qiao B, Kerr M, Groselj B, Teo MT, Knowles MA, Bristow RG, Phillips RM, Kiltie AE (2013) Imatinib radiosensitizes bladder cancer by targeting homologous recombination. Cancer Res 73:1611–1620PubMedCentralPubMedCrossRef Qiao B, Kerr M, Groselj B, Teo MT, Knowles MA, Bristow RG, Phillips RM, Kiltie AE (2013) Imatinib radiosensitizes bladder cancer by targeting homologous recombination. Cancer Res 73:1611–1620PubMedCentralPubMedCrossRef
41.
Zurück zum Zitat Hardee ME, Marciscano AE, Medina-Ramirez CM, Zagzag D, Narayana A, Lonning SM, Barcellos-Hoff MH (2012) Resistance of glioblastoma-initiating cells to radiation mediated by the tumor microenvironment can be abolished by inhibiting transforming growth factor-beta. Cancer Res 72:4119–4129PubMedCentralPubMedCrossRef Hardee ME, Marciscano AE, Medina-Ramirez CM, Zagzag D, Narayana A, Lonning SM, Barcellos-Hoff MH (2012) Resistance of glioblastoma-initiating cells to radiation mediated by the tumor microenvironment can be abolished by inhibiting transforming growth factor-beta. Cancer Res 72:4119–4129PubMedCentralPubMedCrossRef
42.
Zurück zum Zitat Xue J, Li X, Lu Y, Gan L, Zhou L, Wang Y, Lan J, Liu S, Sun L, Jia L et al (2013) Gene-modified mesenchymal stem cells protect against radiation-induced lung injury. Mol Ther 21:456–465PubMedCentralPubMedCrossRef Xue J, Li X, Lu Y, Gan L, Zhou L, Wang Y, Lan J, Liu S, Sun L, Jia L et al (2013) Gene-modified mesenchymal stem cells protect against radiation-induced lung injury. Mol Ther 21:456–465PubMedCentralPubMedCrossRef
43.
Zurück zum Zitat Magne N, Chargari C, MacDermed D, Conforti R, Vedrine L, Spano JP, Khayat D (2010) Tomorrow’s targeted therapies in breast cancer patients: what is the risk for increased radiation-induced cardiac toxicity? Crit Rev Oncol Hematol 76:186–195PubMedCrossRef Magne N, Chargari C, MacDermed D, Conforti R, Vedrine L, Spano JP, Khayat D (2010) Tomorrow’s targeted therapies in breast cancer patients: what is the risk for increased radiation-induced cardiac toxicity? Crit Rev Oncol Hematol 76:186–195PubMedCrossRef
Metadaten
Titel
Mesenchymal stem cells are sensitive to treatment with kinase inhibitors and ionizing radiation
verfasst von
Nils H. Nicolay, M.D., Ph.D.
Eva Sommer, D.V.M.
Ramon Lopez Perez, M.Sc.
Ute Wirkner, Ph.D.
Tilman Bostel, M.D.
Anthony D. Ho, M.D.
Michael Lahn, Ph.D.
Jürgen Debus, M.D., Ph.D.
Rainer Saffrich, Ph.D
Peter E. Huber, M.D., Ph.D
Publikationsdatum
01.10.2014
Verlag
Springer Berlin Heidelberg
Erschienen in
Strahlentherapie und Onkologie / Ausgabe 11/2014
Print ISSN: 0179-7158
Elektronische ISSN: 1439-099X
DOI
https://doi.org/10.1007/s00066-014-0686-1

Weitere Artikel der Ausgabe 11/2014

Strahlentherapie und Onkologie 11/2014 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.